Renal Denervation Devices Market Seen Reaching $3.01 Billion by 2030

The renal denervation devices market is projected to expand from $0.98 billion in 2026 to $3.01 billion by 2030, driven by resistant hypertension, broader clinical adoption and more regulatory approvals. Europe led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - Renal denervation devices are being positioned as a minimally invasive option for people with resistant hypertension who do not respond well to medication. - The market’s projected growth reflects rising demand for long-term blood pressure control beyond drug-based treatment. - Hypertension remains a major public health burden, with the CDC reporting in January 2025 that high blood pressure was responsible for or contributed to 664,470 deaths in the U.S. in 2023.

What happened: - The Business Research Company projected the renal denervation devices market would rise from $0.74 billion in 2025 to $0.98 billion in 2026. - The report forecast the market will reach $3.01 billion by 2030, implying a 32.4% CAGR. - The company said Europe held the largest global market share in 2025. - The company said Asia-Pacific will be the fastest-growing region during the forecast period. - The report was released August 28, 2026, in London. - Download a free sample of the report. - View the full market report.

The details: - Renal denervation devices work by inserting a catheter into the renal arteries. - Radiofrequency energy is then applied to ablate sympathetic nerves in the vessel walls. - The nerve ablation is intended to reduce nerve activity, improve blood flow to the kidneys and lower blood pressure. - The market’s recent expansion was linked to rising resistant hypertension, catheter ablation advances, more clinical research, wider use of interventional cardiology procedures and greater awareness of non-drug hypertension treatments. - The report said future growth will be supported by more regulatory approvals, stronger demand for outpatient interventions and expanding clinical evidence on effectiveness. - The report also highlighted next-generation ablation technology, broader catheter-based hypertension therapies, radiofrequency and ultrasound use, image-guided procedures and a greater focus on safety and precision. - The report covered Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - New 2026 report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated technology and trend analysis.

Between the lines: - The forecast suggests renal denervation is moving from a niche investigational approach toward a more established interventional category. - Faster growth in Asia-Pacific points to expanding healthcare access and research activity as important demand drivers outside mature Western markets. - Strong projected growth also signals that device makers may see opportunity in minimally invasive cardiovascular procedures, especially if regulatory momentum continues.

What's next: - The market’s trajectory will likely depend on additional approvals, broader physician adoption and continued clinical data on safety and durability. - Adoption could accelerate if outpatient and image-guided procedures become more common. - The competitive focus is likely to shift toward precision, safety and next-generation ablation systems.

The bottom line: - Renal denervation devices are projected to post rapid, sustained growth through 2030 as resistant hypertension pushes demand for minimally invasive treatment options.